Skip to main content

STAT reports that the FDA has created a new regulatory category for the supplement NAC, which has long been available but operated in a legal gray area. The decision follows advocacy from MAHA and is seen as a shift in how supplements may be regulated in the future.

This matters for pharma and biotech executives because regulatory clarity can affect compliance, market access, and future product strategies. The move may signal further changes in supplement oversight, making it important for regulated firms to track similar developments.

A new Trump administration regulation aims to address fraud, with all of the anticipated savings expected to come from Medicare Advantage, according to STAT. The regulation is intended to target so-called 'fraudsters' in the programme, which is a major part of the US health insurance market.

This move signals increased regulatory attention on Medicare Advantage, which may affect how health insurers and providers manage billing and compliance. Senior executives in health insurance and healthcare should review their risk controls and prepare for possible audits or reimbursement changes.

STAT reports that Biogen is preparing to announce results from a pivotal clinical trial of its experimental lupus therapy. The readout is expected soon, according to the source.

This matters for senior pharma and biotech executives because the trial outcome could influence development strategies, portfolio priorities and market competition in autoimmune disease. The results may also affect future investment and partnership opportunities in the lupus space.

STAT reports that the FDA has ended the fast-track drug review initiative started in June 2025 under former Commissioner Marty Makary. No further details on the reasons or next steps were provided.

This decision could slow approval processes for new drugs, which matters for pharma and biotech executives managing regulatory risk and market entry. Companies should monitor for further guidance from the FDA.

STAT says new documents have raised further questions about Medicare’s AI prior-authorisation experiment. The article points to ongoing scrutiny of how artificial intelligence is being used in healthcare authorisation processes.

This matters for healthcare executives and insurers as it signals persistent regulatory and operational uncertainty. The results may affect future adoption of AI in clinical settings and how authorisation decisions are made.

Pfizer spent up to $10 billion to acquire Metsera last year, according to STAT. The company is now involving private equity firm Blackstone to help finance the deal, reflecting a trend of outside investors entering major pharmaceutical transactions.

This partnership signals the increasing appeal of obesity treatments to both pharma companies and private equity. For senior executives, the deal points to new financing models and rising competition in a high-growth therapeutic area. Further deals involving private equity could follow as the sector evolves.

PHI Health, a national air ambulance provider, is suing employers across the US for unpaid out-of-network medical helicopter bills, with individual claims reaching nearly $27,000. The lawsuits target both small businesses and large corporations, as well as public sector entities and nonprofits, according to STAT. Previously, providers sought payment from insurers, but are now increasingly pursuing employers directly after winning arbitration awards under the No Surprises Act.

The 2022 No Surprises Act was intended to protect patients from unexpected medical bills, but its arbitration process has led to higher payments for out-of-network providers. Georgetown University researchers estimate this has added around $20 billion in extra costs to the health care system, much of which is passed on to employers and workers through higher premiums. PHI Health has filed lawsuits against hundreds of companies, sometimes naming unknown defendants as placeholders if the plan sponsor is unclear.

Legal experts say this tactic shifts the financial burden from insurers to the employers who sponsor health plans, undermining claims that insurers are solely responsible for payment delays. The litigation adds complexity and risk for organisations managing employee health benefits, with the potential for further escalation as more providers adopt this approach.

STAT reports that federal health officials granted broad ethics waivers to members of the US Preventive Services Task Force, with some panel members holding pharmaceutical shares or running private medical practices. These waivers allow participation despite financial interests that could be affected by panel recommendations.

This raises questions for pharma and healthcare leaders about the impartiality of federal preventive care guidance. Senior executives should monitor for any regulatory or policy changes that could affect how conflicts of interest are managed in health policy bodies.

STAT reports that drug companies are seeking ways to shield their US sales from the effects of the Trump administration's 'most-favored nations' policy. The policy aims to align US drug prices with those in other developed countries, prompting firms to reconsider how and where they introduce new medicines abroad.

This shift could delay or alter drug launches outside the US, affecting market access and patient availability in Europe and elsewhere. Pharma leaders need to track these policy changes closely, as they may influence revenue forecasts and regulatory strategies for international markets.

STAT reports that Texas, Georgia, and Wisconsin could expand their Medicaid programmes following Democratic wins. The article says this shift would make more than a million people newly eligible for health coverage if the expansions go ahead.

For health insurers and providers, this may mean a larger covered population and changes in state-level funding. Senior executives in healthcare and insurance should monitor legislative developments in these states, as policy changes could affect contracts, claims, and risk pools.